Innovative Employer Models: Incorporating Biosimilars into Health Plan Drug Formularies

ISSUE BRIEF

In a new report released by The ERISA Industry Committee (ERIC), a majority of member companies stated they would consider shifting away from the “Traditional Rebate Model” if they were able to achieve savings by including lower list price drugs like biosimilars on their formulary. The report, “Innovative Employer Models: Incorporating Biosimilars into Health Plan Drug Formularies,” identifies biosimilars as a tool for employers to reduce their spending on prescription drugs while maintaining access to high-quality, clinically equivalent treatments for their employees, and highlights several major employers that have taken proactive, innovative approaches to driving value in their pharmacy benefits.

Access the full report here.

WEBINAR: December 2, 2025 at 3:00 p.m. 

ERIC also invites you to join them for a webinar on December 2 at 3:00 p.m. (ET), where they will dive deeper into the findings and implications of the report. During this webinar, they will:

  • Explore how employers are transforming their benefit plans and using biosimilars to reduce spending on prescription drugs
  • Discuss current challenges with the “Traditional Rebate Model”
  • Discuss the report’s implications for employers, patients, and policymakers

Sandoz, Blue Shield of California, Amazon, and health policy experts will present during the webinar, sharing an inside look at the innovative benefit design strategies they have implemented to maximize value for employees.

To register for the webinar, please click here.